Orziloben is a synthetic medium-chain fatty acid (MCFA) analogue. Contrary to earlier assumptions of it being a nonsteroidal anti-inflammatory drug (NSAID), recent data indicate that Orziloben is not classified as an NSAID. Instead, it is under investigation for treating metabolic and liver diseases, particularly intestinal failure-associated liver disease (IFALD). Preclinical studies have demonstrated its potential in preventing hepatosteatosis and reducing inflammatory lipid metabolites in animal models. Orziloben exhibits anti-inflammatory, analgesic, and antipyretic effects, likely through cyclooxygenase (COX) inhibition, similar to other fenamates. Its activity includes the suppression of prostaglandin synthesis, contributing to reduced inflammation and pain.
MedKoo Cat#: 140240
Name: Orziloben
CAS#: 1555822-28-0
Chemical Formula: C13H18O3
Exact Mass: 222.1256
Molecular Weight: 222.28
Elemental Analysis: C, 70.24; H, 8.16; O, 21.59
The following data is based on the product molecular weight 222.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
